Online inquiry

IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15086MR)

This product GTTS-WQ15086MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNC gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_002160.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3371
UniProt ID P24821
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15086MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12835MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ14694MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ10345MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ5631MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ5597MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ12139MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ11694MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ10190MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW